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Fragile X testing is a priority in the evaluation of autism spectrum
disorders (ASD) cases because identification of the FMR1 mutation leads
to new treatment options. This study is focused on determining the
prevalence of the FMR1 gene mutation among ASD cases in Indonesia.
DSM-IV-TR criteria were administered to diagnose ASD; symptom
severity was classified using the Childhood Autism Rating Scale.
Cytogenetic analysis, polymerase chain reaction, and Southern blot for
FMR1 gene analysis were carried out to confirm the diagnosis of fragile X
syndrome. The fragile X site and FMR1 full mutation allele were
identified in 3 out of 65 (4.6%) and 4 out of 65 (6.15%) children aged
3–17 years (57 boys and 8 girls), respectively. The Fragile X laboratory
workup is essential in the evaluation of patients with ASD. Molecular
analysis is most accurate, while cytogenetic documentation of the fragile X
site can also be useful if molecular testing is not available.
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Autism is a neurobehavioral disorder characterized by
language delay; social and communication impairment;
and repetitive and stereotypic behavior. The prevalence
of autism among children in United State increased
enormously from 0.6 to 6.7 per 1000 from 1990s to
2000s (1, 2). The overall prevalence of autism spectrum
disorders (ASD) is currently 11.3 per 1000 (1 in 88) in
United States (3). Boys are affected four times more
frequently than girls (3).
Fragile X syndrome (FXS) is the most common
inherited cause of intellectual disability (ID) and ASD.
FXS is usually caused by a full mutation in the Fragile
X Mental Retardation 1 gene (FMR1 ) leading to the
gene silencing and the absence of fragile X mental
retardation protein (FMRP). The prevalence of the full
mutation allele is 1 in 2500–3600 (4, 5), but the
penetrance of ID is lower at 1 per 3600–4000 males
and 1 per 8000 females (6, 7) because of mosaicism in
males and X inactivation in females.
Anxiety and social deficits are core clinical features
of FXS and they are also associated with autism in
both males and females (8–10). Autism is diagnosed in
30% of boys with FXS and another 30% are diagnosed
with pervasive developmental disorder not otherwise
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specified (PDD NOS) (11). Those with FXS and autism
have lower cognitive, adaptive, motor and language
abilities compared to those with FXS without autism
(12–15).
FXS is the most common single gene disorder asso-
ciated with autism and it causes 2–6% of autism
cases (16, 17). Therefore, all individuals with ASD
should be tested for the FMR1 mutation (18). ASD
and FXS have similar symptoms and shared molec-
ular mechanisms because FMRP regulates translation
of many other genes also associated with autism and
involved with synaptic plasticity (19, 20). Therefore
the absence of FMRP leads to abnormal spine mat-
uration and morphology, imbalances between exci-
tatory and inhibitory pathways, and the reduction
of brain serotonin synthesis which are also seen in
other forms of autism (19–21). Furthermore, advanced
studies in FXS have improved understanding of the
neurochemical basis of autism and the use of tar-
geted treatments which have benefited those with FXS
and potential to benefit those with idiopathic autism
(22–25).
Methods
Sixty-five children aged 3–17 who were diagnosed with
ASD using the criteria in the Diagnostic and Statistical
Manual of Mental Disorders, 4th edition, Text Revision
(DSM IV-TR) for ASD by experienced pediatricians
were recruited (26). The DSM IV-TR required deficits
in (1) social interaction; (2) communication; and
(3) restricted repetitive and stereotyped patterns of
behavior, interests, and activities, to be present prior
to 3 years old for a diagnosis of ASD.
The severity of autism symptoms was classified
using the Childhood Autism Rating Scale (CARS)
(27), a behavior rating scale to classify autism severity
(28). A threshold score for autism was 30, a score
of 30–36.5 was considered mild-moderate and 37 or
greater was considered severe autism. This research
was approved by the Institutional Review Board of the
Faculty of Medicine, Diponegoro University and the
Kariadi Hospital Semarang, Indonesia, all participants
signed an approved consent form to participate in this
study.
Heparinized peripheral blood vein was collected
for cytogenetic analysis of the fragile site at Xq27.3
as done previously (29). DNA was extracted from
ethylenediaminetetraacetic acid blood using modified
salting out method (30).
The fragile site was identified using solid staining
followed by Giemsa staining for fragile X site confir-
mation. The FMR1 gene was analyzed using a poly-
merase chain reaction-based method to determine the
CGG repeat length in the promotor region as described
previously (31). Males with no bands and females with
only one band were assumed to have alleles consisting
of high premutation or full mutation alleles, therefore,
Southern blot analysis was utilized to confirm the diag-
nosis (31).
Table 1. Childhood Autism Rating Scale (CARS) categorical
diagnosis of all children (n=65)
CARS categories Male Female Total
Mildly to moderately autistic 20 5 25
Severely autistic 37 3 40
Results
The results of the assessment of clinical features in
the 65 children are summarized in Table 1. One child
was diagnosed with PDD NOS and all other children
had autism. The fragile X site located at Xq27.3 was
identified in 3 out of 65 (4.5%) children (see Fig. 1).
Four out of 65 (61.5%) children had expanded alleles
of FMR1 gene in the full mutation range. These alleles
were confirmed by Southern blot.
All children with ASD who carried FMR1 full
mutation alleles were impaired in social interaction
and communication domains, and had at least two
out of four subdomains in the restricted repetitive and
stereotyped patterns of behavior, interests, and activities
domain. The phenotypic expression of ASD using the
CARS addressed the severity of autism which ranged
from mildly to severely autistic (see Tables 1 and 2).
Discussion
A genetic workup is critical to establish the etiology of
ASD and determine appropriate treatments, particularly
targeted treatments in addition to behavioral interven-
tions and genetic counseling (32). This study confirms
the higher rate of FXS (6.15%) compare to those of
previous small population studies (33, 34).
Cytogenetic techniques have been used to diagnose
FXS through the expression of the fragile X site until
the late 1990s (35), and have been abandoned due
to low sensitivity compared to molecular techniques
(36). However, in developing countries where advanced
laboratory equipments and services are very minimal
and unaffordable, cytogenetic techniques are still an
option to accomplish the FXS diagnosis (37). However,
only 75% of children who carried the full mutation
allele exhibit the fragile X site in this study (see
Table 2). Although the sensitivity is lower than that
of DNA testing, the fragile X site expression can still
identify a positive result when DNA testing is not
available.
Over the past three decades, ASD has been a concern
to those diagnosed with FXS because the additional
diagnosis of ASD is associated with a greater severity
of developmental delay (14), motor and language
impairments (15), and social deficits (38). Other genetic
disorders are also known to contribute to ASD such as
Prader-Willi syndrome, Angelman syndrome, Tuberous
Sclerosis, and Smith-Lemli-Opitz syndrome (39–41),
but FXS is the most common known genetic cause of
autism, likely because FMRP controls the translation
of many genes important for synaptic plasticity and
associated with autism (42).
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Fig. 1. Representative of Giemsa-banding fragile X site (Xq27.3) of case 1. Black arrows indicate fragile site in the long arm of X chromosome
both in metaphase (a) and 46,XY fax(X)(q27.3) karyotype (b).
Table 2. Cytogenetic, molecular status, and clinical characteristics of four autism cases caused by fragile X syndrome
Fragile X syndrome Case 1 Case 2 Case 3 Case 4
Sex Male Male Male Male
Age (year) 12 9 6 4
Fragile X site (Xq27.3) 17% 34% 0% 24%
FMR1 allele Full mutation Full mutation Full mutation Full mutation
DSM IV score
1. Social interaction
2. Communication
3. Repetitive, stereotype
and restricted patterns
of behavior and interests
4
4
3
4
4
2
4
4
3
2
2
2
CARS categories Severely autistic Severely autistic Mildly to moderate
autistic
Mildly to moderate
autistic
CARS, Childhood Autism Rating Scale.
Impairment of social communication and interaction
domains have been found to be dominant in four FXS
children with ASD compared to those of repetitive,
stereotypic and restricted patterns of behavior and
interests domain (see Table 2). These characteristics are
consistent with previous studies (38, 43). The degree of
autism symptoms severity varies from mild to severe
in this study (see Table 2). A recent study by Smith
et al. indicated that individuals who were diagnosed
FXS with ASD displayed greater communication and
social reciprocity impairments than individuals with
FXS without autism (44). Our study confirms that the
social and communication deficits are most predictive
of ASD in those with FXS.
Individuals with idiopathic autism compared to
those of complex autism, such as FXS, is consid-
ered better prognosis (32). However, as FXS leads
the way to targeted treatments with initial studies
demonstrating efficacy in a subgroup of FXS with
mGluR5 antagonists (45), a GABA B agonist, and
arbaclofen (46), it is likely that those with FXS
may have the best prognosis with new targeted treat-
ments. However, initial studies have demonstrated
that the mouse models of idiopathic autism (23) and
some human studies in autism may also respond
to mGluR5 antagonists and GABA agonists (22,
47). A randomized, double-blind, placebo-controlled
phase 2 study of STX209 (arbaclofen and R-baclofen)
in ASD was completed but not yet published to
address social withdrawal (www.clinicaltrials.gov or
www.seasidetherapeutics.com). It is likely that further
studies to address efficacy of targeted treatments in both
FXS and autism will be beneficial. Discovering the
cause of ASD is an important step not only to estab-
lish appropriate intervention and treatment, but also to
carry out genetic counseling that will inform the recur-
rent risk of FXS and fragile X-associated disorders in
the family.
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